Trial Profile
A Multi-centre, Open-label, Single-group Exploratory Trial of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2024
Price :
$35
*
At a glance
- Drugs Sparsentan (Primary)
- Indications IgA nephropathy
- Focus Therapeutic Use
- Acronyms SPARTAN
- 03 Apr 2024 According to a Travere Therapeutics media release, preliminary findings from this trial will be presented at the World Congress of Nephrology (WCN) in Buenos Aires, Argentina, on April 13-16, 2024.
- 08 Jan 2024 According to a Travere Therapeutics media release, additional data from this study expected in 2024.
- 13 Oct 2023 According to a Travere Therapeutics media release, the study is fully enrolled, with final readout scheduled for 2025.